Health Canada Approves Mirum Pharma's Livmarli Tablet Formulation; Stock Up

Mirum Pharmaceuticals, Inc. (MIRM) on Thursday said Health Canada has approved the tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). Following the announcement, the company's shares rose more than 5% in pre-market trading.ALGS is a rare genetic disorder that affects multiple organ systems, including the liver, where bile duct abnormalities can lead to cholestasis and severe itching, known as pruritus.Livmarli was previously approved in Canad ...